Theragnostics, An Issue of PET Clinics

Theragnostics trials, neuroendocrine tumors, prostate-specific membrane antigen, theragnostics post-therapy imaging, fibroblast-activation-protein inhibitors (FAPI) theragnostics, and more are covered in this issue of PET Clinics. Guest editors Drs. Andrei Iagaru and Heather A. Jacene provide in-depth clinical reviews on the topic, offering actionable insights for clinical practice.

Format: Hardback
Length: 240 pages
Publication date: 06 June 2024
Publisher: Elsevier Health Sciences

Theragnostics is a rapidly evolving field that combines therapeutic and diagnostic approaches to improve patient outcomes. PET Clinics, a leading journal in the field, has recently published a special issue dedicated to this topic, featuring 12 relevant, practice-oriented topics. These topics include theragnostics trials, neuroendocrine tumors: diagnostics, prostate-specific membrane antigen: diagnostics, theragnostics: post-therapy imaging, fibroblast-activation-protein inhibitors (FAPI) theragnostics, and more.

The special issue begins with a comprehensive clinical review on theragnostics, providing actionable insights for clinical practice. The authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

In the first article, Drs. Andrei Iagaru and Heather A. Jacene discuss neuroendocrine tumors: beta-labeled peptides. They highlight the importance of these peptides in the diagnosis and treatment of neuroendocrine tumors, and discuss the latest developments in their use.

Next, Drs. Iagaru and Jacene examine prostate-specific membrane antigen: interpretation criteria, standardized reporting, and the use of artificial intelligence. They discuss the challenges associated with interpreting prostate-specific membrane antigen (PSMA) imaging and the potential benefits of using artificial intelligence to improve accuracy.

The issue also includes a review on prostate cancer (gastrin-releasing peptide receptor). The authors discuss the role of this receptor in the development of prostate cancer and the potential for targeted therapy. They also highlight the latest developments in selective internal radiation therapy (SIRT) and its potential for improving patient outcomes.

In addition to these clinical reviews, the special issue includes several original research articles. These articles explore the use of theragnostics in various cancer types, including lung cancer, breast cancer, and gastrointestinal cancer. The authors discuss the advantages of using theragnostics, as well as the challenges associated with their implementation.

One of the key challenges in theragnostics is the development of new imaging agents. PET Clinics has published several articles on the development of new imaging agents, including FAPI theragnostics. FAPI theragnostics is a novel imaging agent that targets fibroblast-activation-protein, which is overexpressed in many cancer types. The authors discuss the potential benefits of FAPI theragnostics, as well as the challenges associated with its development and use.

Another important aspect of theragnostics is the integration of imaging and therapy. PET Clinics has published several articles on the integration of imaging and therapy, including the use of PET/CT imaging to guide radiation therapy. The authors discuss the advantages of this approach, as well as the challenges associated with its implementation.

In conclusion, PET Clinics' special issue on Theragnostics is a valuable resource for clinicians and researchers in the field. The issue features 12 relevant, practice-oriented topics, and provides actionable insights for clinical practice. The clinical reviews and original research articles highlight the latest developments in theragnostics, and the integration of imaging and therapy. By reading this issue, clinicians can stay up-to-date on the latest research and practice guidelines, and improve patient outcomes.

Weight: 500g
Dimension: 185 x 264 x 13 (mm)
ISBN-13: 9780443129216